Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Context Therapeutics Inc. - Common Stock
(NQ:
CNTX
)
1.470
+0.170 (+13.08%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Context Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
December 16, 2025
Issued on behalf of Oncolytics Biotech Inc.
From
Equity Insider
Via
GlobeNewswire
Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting
November 07, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results
November 05, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics to Participate in Upcoming Investor Conferences
October 28, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
October 06, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
This Synopsys Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday
↗
October 02, 2025
Via
Benzinga
Context Therapeutics to Participate in Upcoming Investor Conferences
August 27, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
CONTEXT THERAPEUTICS INC (NASDAQ:CNTX) Posts Wider Q2 2025 Loss Amid Continued Pipeline Progress
↗
August 06, 2025
Context Therapeutics reports Q2 2025 loss of $0.09 per share, missing estimates. Pipeline advances with Phase 1 trials for CTIM-76 and CT-95, but shares drop 14.3% post-earnings. Cash runway extends to...
Via
Chartmill
Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results
August 06, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
June 05, 2025
Via
Benzinga
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
June 02, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
May 29, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 12, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
May 07, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Announces Chief Medical Officer Transition
May 05, 2025
Board Member Dr. Karen Smith to serve as Interim Chief Medical Officer
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting
April 30, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
April 09, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Unusual volume stocks in Friday's session
↗
April 04, 2025
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
Via
Chartmill
These stocks that are showing activity before the opening bell on Thursday.
↗
April 03, 2025
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via
Chartmill
Context Therapeutics to Participate in Upcoming Investor Conferences
April 01, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
March 26, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Top movers analysis one hour before the close of the markets on 2025-03-25: top gainers and losers in today's session.
↗
March 25, 2025
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Via
Chartmill
Context Therapeutics Reports Full Year 2024 Operating and Financial Results
March 20, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
March 17, 2025
Via
Benzinga
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 24, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics to Participate in Upcoming Investor Conferences
February 19, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
January 15, 2025
Via
Benzinga
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
January 14, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
January 13, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.